Cidara Therapeutics discloses Nasdaq listing deficiency notice

Cidara Therapeutics “announced on April 17, 2024, that the Company received a notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC advising the Company that its failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 with the Securities and Exchange Commission, in contravention of Nasdaq Listing Rule 5250(c)(1), could serve as an additional deficiency and basis for the delisting of the Company’s securities from Nasdaq.”